



FORM PTO-1390 (REV 10-95)		U S DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTORNEY'S DOCKET NUMBER SCH 1867
TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. §371			U S APPLICATION NO (If known, see 37 CFR §1.5) 10/031198
INTERNATIONAL APPLICATION NO PCT/DE00/02390	INTERNATIONAL FILING DATE 17 JULY 2000	PRIORITY DATE CLAIMED 15 JULY 1999	
TITLE OF INVENTION NOVEL C-19-HALOGEN-SUBSTITUTED STEROIDS OF THE ANDROST-9(11)-ENE-SERIES, METHODS FOR THE PRODUCTION AND USE THEREOF			
APPLICANT(S) FOR DO/EO/US NEEF, Gunter, et al.			
<p>Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:</p> <ol style="list-style-type: none"> <input checked="" type="checkbox"/> This is a FIRST submission of items concerning a filing under 35 U.S.C. §371 <input type="checkbox"/> This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. §371. <input type="checkbox"/> This express request to begin national examination procedures (35 U.S.C. §371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. §371(b) and PCT Articles 22 and 39(1). <input checked="" type="checkbox"/> A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date <input checked="" type="checkbox"/> A copy of the International Application as filed (35 U.S.C. §371(c)(2)) <ol style="list-style-type: none"> <input type="checkbox"/> is transmitted herewith (required only if not transmitted by the International Bureau). <input checked="" type="checkbox"/> has been transmitted by the International Bureau <input type="checkbox"/> is not required, as the application was filed in the United States Receiving Office (RO/US). <input type="checkbox"/> A translation of the International Application into English (35 U.S.C. §371(c)(2)). <input checked="" type="checkbox"/> Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. §371(c)(3)) <ol style="list-style-type: none"> <input type="checkbox"/> are transmitted herewith (required only if not transmitted by the International Bureau) <input type="checkbox"/> have been transmitted by the International Bureau. <input type="checkbox"/> have not been made, however, the time limit for making such amendments has NOT expired. <input checked="" type="checkbox"/> have not been made and will not be made. <input type="checkbox"/> A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. §371(c)(3)). <input type="checkbox"/> An oath or declaration of the inventor(s) (35 U.S.C. §371(c)(4)) <input type="checkbox"/> A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. §371(c)(5)). <p>Items 11. to 16. below concern document(s) or information included:</p> <ol style="list-style-type: none"> <input type="checkbox"/> An Information Disclosure Statement under 37 C.F.R. §§1.97 and 1.98. <input type="checkbox"/> An assignment document for recording. A separate cover sheet in compliance with 37 C.F.R. §§3.28 and 3.31 is included. <input type="checkbox"/> A FIRST preliminary amendment. <input type="checkbox"/> A SECOND or SUBSEQUENT preliminary amendment. <input type="checkbox"/> A substitute specification. <input type="checkbox"/> A change of power of attorney and/or address letter. <input type="checkbox"/> Other items or information: 			

531 Rec'd PCT/P

15 JAN 2002

U.S. APPLICATION NO (if known, see 37 CFR § 1.53) 10/031198				INTERNATIONAL APPLICATION NO PCT/DE00/02390		ATTORNEY'S DOCKET NUMBER SCH 1867	
17. <input checked="" type="checkbox"/> The following fees are submitted:						CALCULATIONS PTO USE ONLY	
BASIC NATIONAL FEE (37 CFR §1.492 (a) (1) - (5)):							
Search Report has been prepared by the EPO or JPO.....					\$890.00		
International preliminary examination fee paid to USPTO (37 CFR §1.482)....					\$710.00		
No international preliminary examination fee paid to USPTO (37 CFR §1.482) but international search fee paid to USPTO (37 CFR §1.445(a)(2)).....					\$740.00		
Neither international preliminary examination fee (37 CFR §1.482) nor international search fee (37 CFR §1.445(a)(2)) paid to USPTO.....					\$1040.00		
International preliminary examination fee paid to USPTO (37 CFR §1.482) and all claims satisfied provisions of PCT Article 33(2)-(4).....					\$100.00		
ENTER APPROPRIATE BASIC FEE AMOUNT =						\$890.00	
Surcharge of \$130.00 for furnishing the oath or declaration later than months from the earliest claimed priority date (37 C.F.R. §1.492(e)). <input type="checkbox"/> 20 <input type="checkbox"/> 30							
CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE				
Total claims	- 20 =	0	x \$ 18.00			\$0.00	
Independent claims	- 3 =	0	x \$ 84.00			\$0.00	
MULTIPLE DEPENDENT CLAIM(S) (if applicable)			+ \$ 280.00				
TOTAL OF ABOVE CALCULATIONS =						\$890.00	
Reduction of 1/2 for filing by small entity, if applicable. A Verified Small Entity Statement must also be							
SUBTOTAL =						\$890.00	
Processing fee of \$130.00 for furnishing the English translation later than months from the earliest claimed priority date (37 C.F.R. §1.492(f)). <input type="checkbox"/> 20 <input type="checkbox"/> 30							
TOTAL NATIONAL FEE =						\$890.00	
Fee for recording the enclosed assignment (37 C.F.R. §1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 C.F.R. §§3.28, 3.31). \$40.00 per property.							
TOTAL FEES ENCLOSED =						\$890.00	
						Amount to be refunded:	
						charged:	
<p>a. <input checked="" type="checkbox"/> A check in the amount of <u>\$890.00</u> to cover the above fees is enclosed.</p> <p>b. <input type="checkbox"/> Please charge my Deposit Account No. <u>13-3402</u> in the amount of \$_____ to cover the above fees. A duplicate copy of this sheet is enclosed.</p> <p>c. <input checked="" type="checkbox"/> The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. <u>13-3402</u>. A duplicate copy of this sheet is enclosed.</p>							
<p>NOTE: Where an appropriate time limit under 37 C.F.R. §§1.494 or 1.495 has not been met, a petition to revive (37 C.F.R. §1.137(a) or (b)) must be filed and granted to restore the application to pending status.</p>							
SEND ALL CORRESPONDENCE TO, Customer Number 23,599							
 23599 PATENT TRADEMARK OFFICE				SIGNATURE  Anthony J. Zelano NAME 27,969 REGISTRATION NUMBER			
Filed: 15 JANUARY 2002 AJZ/kmo							

10 Recd JUL 2 2002

Docket No. SCH 1867

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: NEEF, Gunter, et al

GAU:

SERIAL NO: 10/031,198

EXAMINER:

FILING DATE: 15 JANUARY 2002

FOR: NOVEL C-19-HALOGEN-SUBSTITUTED STEROIDS OF THE ANDROST-9(11)-ENE-SERIES,
METHODS FOR THE PRODUCTION AND USE THEREOF**AMENDMENT TRANSMITTAL**ASSISTANT COMMISSIONER FOR PATENTS
WASHINGTON, D.C. 20231

SIR:

Transmitted herewith is an amendment in the above-identified application.

- ☐ No additional fee is required.
- ☐ Applicant(s) is/are entitled to small entity status.
- ☒ Additional documents filed herewith:

The fee has been calculated below:

CLAIMS	CLAIMS REMAINING		HIGHEST NO. PREVIOUSLY PAID FOR	NO. OF EXTRA CLAIMS	RATE		CALCULATIONS
TOTAL	23	MINUS	20	3	x	\$18 =	\$54.00
INDEPENDENT	4	MINUS	3	1	x	\$84 =	\$84.00
<input type="checkbox"/> MULTIPLE DEPENDENT CLAIMS							
TOTAL OF ABOVE CALCULATIONS							\$0.00
<input type="checkbox"/>							
<input type="checkbox"/> REDUCTION BY 50% FOR FILING BY SMALL ENTITY							\$0.00
<input type="checkbox"/> RECORDATION OF ASSIGNMENT					+	\$40 =	\$0.00
TOTAL							\$138.00

- ☐ A check in the amount of \$138.00 is attached.
- ☒ Please charge any additional fees for the papers being filed herewith and for which no check is enclosed herewith, or credit any overpayment to Deposit Account No. 13-3402. A duplicate copy of this sheet is enclosed.
- ☒ If these papers are not considered timely filed by the Patent and Trademark Office, then a petition is hereby made under 37 C.F.R. § 1.136, and any additional fees required under 37 C.F.R. § 1.36 for any necessary extension of time may be charged to Deposit Account No. 13-3402. A duplicate copy of this sheet is enclosed.

Respectfully submitted,

Anthony J. Zelano (33103) for
 Anthony J. Zelano Atty., Registration No. 27,969
 Attorney/Agent for Applicants

MILLEN, WHITE, ZELANO
 & BRANIGAN, P.C.
 Arlington Courthouse Plaza I
 2200 Clarendon Blvd. Suite 1400
 Arlington, Virginia 22201
 Telephone: (703) 243-6333
 Facsimile: (703) 243-6410
 Date: 2 JULY 2002

IN THE UNITED STATES DESIGNATED/ELECTED OFFICE

International Application No. : PCT/DE00/02390
International Filing Date : 17 JULY 2000
Priority Date(s) Claimed : 15 JULY 1999
Applicant(s) (DO/EO/US) : NEEF, Gunter, et al

Title: NOVEL C-19-HALOGEN-SUBSTITUTED STEROIDS OF THE ANDROST-9(11)-ENE-SERIES, METHODS FOR THE PRODUCTION AND USE THEREOF

PRELIMINARY AMENDMENT

Commissioner for Patents
Washington, D.C. 20231

SIR:

Prior to calculating the national fee, and prior to examination in the National Phase of the above-identified International application, please amend as follows:

IN THE CLAIMS:

3. (Amended) 17 β -Hydroxy-19-halogen-androsta-4,9(11)-dien-3-ones according to claim 1, characterized by

17 β -Hydroxy-19-iodo-androsta-4,9(11)-dien-3-one,

17 β -Hydroxy-19-¹²⁵I-iodo-androsta-4,9(11)-dien-3-one or

19-Bromo-17 β -hydroxy-androsta-4,9(11)-dien-3-one.

4. (Amended) Process for the production of 17 β -hydroxy-19-halogen-androsta-4,9(11)-dien-3-ones of general formula I according to claim 1, wherein starting from 3,3-(2,2-dimethyl-trimethylenedioxy)-10 β -formyl-androst-9(11)-ene-5 α ,17 β -diol

a) The C-17 β -hydroxy group is protected by silylation,

- b) The 10 β -formyl group is reduced to the C-19-hydroxy compound,
- c) The thus produced 17 β -silylated-3,3-(2,2-dimethyl-trimethylenedioxy)-androst-9(11)-ene-5 α ,19-diol is reacted with elementary halogen or radiohalogen, selected from Br or I, to form 17 β -silylated-3,3-(2,2-dimethyl-trimethylenedioxy)-19-halogen-androst-9(11)-en-5 α -ol,
- d) Water is cleaved off, and
- e) The thus produced isomer mixture that consists of 17 β -silylated-3,3-(2,2-dimethyl-trimethylenedioxy)-19-halogen-androsta-5,9(11)-diene and 17 β -silylated-3,3-(2,2-dimethyl-trimethylenedioxy)-19-halogen-androsta-4,9(11)-diene is mixed with a strong protonic acid for the formation of target compounds I.

6. (Amended) Process according to claim 4, wherein the halogen or radiohalogen is added in a small excess.

7. (Amended) Process according to claim 4, wherein the dehydration is carried out under standard conditions, preferably with thionyl chloride/pyridine.


8. (Amended) Process according to claim 4, wherein trifluoroacetic acid, sulfuric acid or methanesulfonic acid is used as a strong protonic acid.

9. (Amended) Use of the compounds of general formula I according to claim 1 as a diagnostic agent.

11. (Amended) Use of the non-labeled compounds of general formula I according to claim 1 as starting products for the production of 5 β -substituted androst-9(11)-enes of general formula II with radical R in the meaning of: R = -(CH₂)_n-CH₂-R¹, -(CH₂)_n-CH₂-OR¹, -(CH₂)_n-CH₂-OCOR¹, -(CH₂)_n-CH₂-SR¹, -(CH₂)_n-CH₂-NR¹R², -(CH₂)_n-CHO, -(CH₂)_n-CN, in which n can

assume the values of 0-5, and radicals R^1 and R^2 , independently of one another, stand for hydrogen or a straight-chain or branched, saturated or unsaturated hydrocarbon radical with up to 18 C atoms, whereby this radical optionally can contain additional functional groups and carbocyclic or heterocyclic ring elements.

15. (Amended) Use of the non-labeled compounds of general formula I according to claim 1 as starting products for the production of $6\beta,19$ -cycloandrostadienes of general formula III, in which X = O or the grouping 17β -OR, 17α -H, with R in the meaning of H, C1-C10-alkyl, C1-C10-acyl, whereby the acyl radical is derived from an aliphatic or aromatic carboxylic acid.



III


19. (Amended) Process according to claim 17, wherein the base treatment is carried out in an aprotic solvent.

REMARKS

The purpose of this Preliminary Amendment is to eliminate multiple dependent claims in order to avoid the additional fee. Applicants reserve the right to reintroduce claims to canceled combined subject matter.

Attached hereto is a marked-up version of the changes made to the claims by the current amendment. The attached pages are captioned "**Version With Markings to Show Changes Made**".

Respectfully submitted,

 (Reg. 33,103)
Anthony V. Zelano, Reg. No. 27,969
Attorney for Applicants

MILLEN, WHITE, ZELANO & BRANIGAN, P.C.
Arlington Courthouse Plaza 1
2200 Clarendon Boulevard, Suite 1400
Arlington, VA 22201
Direct Dial: 703-812-53
Facsimile: 703-243-6410
Attorney Docket No.:SCH-1867

Date:2 JULY 2002

VERSION WITH MARKINGS TO SHOW CHANGES MADE

3. (Amended) 17 β -Hydroxy-19-halogen-androsta-4,9(11)-dien-3-ones according to one of claims 1 or 2, claim 1, characterized by

17 β -Hydroxy-19-iodo-androsta-4,9(11)-dien-3-one,

17 β -Hydroxy-19-¹²⁵I-iodo-androsta-4,9(11)-dien-3-one or

19-Bromo-17 β -hydroxy-androsta-4,9(11)-dien-3-one.

4. (Amended) Process for the production of 17 β -hydroxy-19-halogen-androsta-4,9(11)-dien-3-ones of general formula I according to one of claims 1 to 3, claim 1, wherein starting from 3,3-(2,2-dimethyl-trimethylenedioxy)-10 β -formyl-androst-9(11)-ene-5 α ,17 β -diol

- a) The C-17 β -hydroxy group is protected by silylation,
- b) The 10 β -formyl group is reduced to the C-19-hydroxy compound,
- c) The thus produced 17 β -silylated-3,3-(2,2-dimethyl-trimethylenedioxy)-androst-9(11)-ene-5 α ,19-diol is reacted with elementary halogen or radiohalogen, selected from Br or I, to form 17 β -silylated-3,3-(2,2-dimethyl-trimethylenedioxy)-19-halogen-androst-9(11)-en-5 α -ol,
- d) Water is cleaved off, and
- e) The thus produced isomer mixture that consists of 17 β -silylated-3,3-(2,2-dimethyl-trimethylenedioxy)-19-halogen-androsta-5,9(11)-diene and 17 β -silylated-3,3-(2,2-dimethyl-trimethylenedioxy)-19-halogen-androsta-4,9(11)-diene is mixed with a strong protonic acid for the formation of target compounds I.

6. (Amended) Process according to claim 4 ~~or 5~~, wherein the halogen or radiohalgen is added in a small excess.

7. (Amended) Process according to ~~one of claims 4 to 6~~, claim 4, wherein the dehydration is carried out under standard conditions, preferably with thionyl chloride/pyridine.


8. (Amended) Process according to ~~one of claims 4 to 7~~, claim 4, wherein trifluoroacetic acid, sulfuric acid or methanesulfonic acid is used as a strong protonic acid.

9. (Amended) Use of the compounds of general formula I according to ~~one of claims 1 to 3~~ claim 1 as a diagnostic agent.

11. (Amended) Use of the non-labeled compounds of general formula I according to ~~one of claims 1 to 3~~ claim 1 as starting products for the production of 5 β -substituted androst-9(11)-enes of general formula II with radical R in the meaning of: $R = -(CH_2)_n-CH_2-R^1$, $-(CH_2)_n-CH_2-OR^1$, $-(CH_2)_n-CH_2-OCOR^1$, $-(CH_2)_n-CH_2-SR^1$, $-(CH_2)_n-CH_2-NR^1R^2$, $-(CH_2)_n-CHO$, $-(CH_2)_n-CN$, in which n can assume the values of 0-5, and radicals R^1 and R^2 , independently of one another, stand for hydrogen or a straight-chain or branched, saturated or unsaturated hydrocarbon radical with up to 18 C atoms, whereby this radical optionally can contain additional functional groups and carbocyclic or heterocyclic ring elements.

15. (Amended) Use of the non-labeled compounds of general formula I according to ~~one of claims 1 to 3~~ claim 1 as starting products for the production of 6 β ,19-cycloandrostadienes of general formula III, in which X = O or the grouping 17 β -OR, 17 α -H, with R in the meaning of H, C1-C10-alkyl, C1-C10-acyl, whereby the acyl radical is derived from an aliphatic or aromatic carboxylic acid.

8



19. (Amended) Process according to claim 17 or 18, wherein the base treatment is carried out in an aprotic solvent.

- (12) INTERNATIONAL APPLICATION PUBLISHED ACCORDING TO THE PATENT COOPERATION TREATY (PCT)
- (19) World Intellectual Property Organization
International Office
- (43) International publication date
January 25, 2001 (1/25/2001) PCT
- (10) International publication number
WO 01/05805 A2
- (51) International patent classification⁷: C07J
- (21) International file number: PCT/DE00/02390
- (22) International application date: July 17, 2000 (7/17/2000)
- (25) Filing language: German
- (26) Publication language: German
- (30) Priority data: 199 34 088.9 July 15, 1999 (7/15/1999) DE
- (71) Applicant (for all designated countries except for the U.S.): SCHERING AKTIENGESSELLSCHAFT [DE/DE]; Müllerstrasse 178, D-13353 Berlin (DE).
- (72) Inventors; and
- (75) Inventors/applicants (only for the U.S.):
NEEF, Günter [DE/DE]; Markgraf-Albrecht-Strasse 4, D-10711 Berlin (DE). GOLDE, Roland [DE/DE]; Schönfliesser Strasse 24, D-16562 Bergfelde (DE). FRITZEMEIER, Karl-Heinrich [DE/DE]; Rabenstrasse 5a, D-13505 Berlin (DE).
- (81) Designated countries (National): AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG,

KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.


(84) Designated countries (Regional): ARIPO Patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian Patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European Patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI Patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:

-- Without international search report and to be republished after receipt of the report.

To clarify the two-letter code, and the other abbreviations, reference is made to the explanations ("Guidance Notes on Codes and Abbreviations") at the beginning of each regular edition of the PCT Gazette.

(54) Title: NEW C-19-HALOGEN-SUBSTITUTED STEROIDS OF THE ANDROST-9(11)-ENE SERIES, PROCESS FOR THEIR PRODUCTION AS WELL AS THEIR USE



(57) **Abstract:** The invention relates to new C-19-halogen-substituted steroids of the androst-9(11)-ene series, namely 17 β -hydroxy-19-halogen-androsta-4,9(11)-dien-3-ones of general formula (I) and process for their production. In addition, the use of new radiohalogen-labeled compounds of Formula (I) as radiopharmaceutical agents is the subject of the invention as well as the use of non-labeled compounds of Formula (I) as starting products for the production of new biologically active 5 β -substituted androst-9(11)-enes of general formula (II) and the new 6 β ,19-cycloandrostadienes of Formula (III) as well as processes for their production and their use.

Optis

10/03/1998

10 Rev 10/03/1998

02 JUL 2002

WO 01/05805

PCT/DE00/02390

New C-19-Halogen-Substituted Steroids of the Androst-9(11)-ene Series, Process for their Production as well as their Use

The invention relates to new C-19-halogen-substituted steroids of the androst-9(11)-ene series, namely 17 β -hydroxy-19-halogen-androsta-4,9(11)-dien-3-ones of general formula I, and process for their production. In addition, the use of the new radiohalogen-labeled compounds of Formula I as radio-pharmaceutical agents is the subject of the invention. These compounds can be used especially preferably in diagnostic studies of the prostate.


Moreover, the invention relates to the use of non-labeled compounds of Formula I as starting products for the production of new biologically active 5 β -substituted androst-9(11)-enes of general formula II and the new 6 β ,19-cycloandrosta-4,9(11)-dienes of Formula III as well as processes for their production and use.

The basic attempt to develop diagnostically and therapeutically usable agents by radioactive labeling of testosterone (17 β -hydroxyandrost-4-en-3-one) is known in the literature (S. J. Brandes and J. E. Katzenellenbogen, Nucl. Med. Biol. 15, 53-67, 1988). The previously used testosterone derivatives have not been introduced into clinical practice, however, in particular because of insufficient tissue selectivity and metabolic instability.

The object of this invention was therefore to find new compounds that are better suited for radiodiagnostic processes.

New 17 β -hydroxy-19-halogen-androsta-4,9(11)-dien-3-ones of general formula I were found that are distinguished by a surprisingly high affinity to the androgen receptor

Formula I



in which

X = a halogen or radiohalogen radical, preferably Br, I, ^{125}I , ^{131}I , ^{82}Br or ^{77}Br .

The compound 17 β -hydroxy-19- ^{125}I -androsta-4,9(11)-dien-3-one represents a preferred radiopharmaceutical agent. The compounds 17 β -hydroxy-19-iodo-androsta-4,9(11)-dien-3-one and 19-bromo-17 β -hydroxy-androsta-4,9(11)-dien-3-one also show a high affinity to the androgen receptor.

The new compounds of general formula I are suitable in particular in the form of the radiohalogen-labeled derivatives for diagnostic use, preferably for graphic visualization of the prostate and for early detection of pathophysiological changes thereof.


The compounds according to the invention are distinguished from known derivatives of testosterone (J. N. Wright et al., J. Chem. Soc. Perkin/1989, 1647-1655) by a 9(11)-double bond. This

structural element opens up the possibility of introducing a functional group at C-19 by a process that is advantageously distinguished from the standard methods for functionalizing a C-19-methyl group (J. Kalvoda et al., *Helv. Chim. Acta* 46, 1361, 1963 and M. Akhtar and D. H. R. Barton, *J. Am. Chem. Soc.* 88, 1528, 1964).

The production of the 17 β -hydroxy-19-halogen-androsta-4,9(11)-dien-3-ones of general formula I according to the invention is carried out according to claim 4, and dependent claims 5 to 8 are preferred variants.

Diagram 1 below shows the synthesis methods according to the invention in the example of 17 β -hydroxy-19-iodo-androsta-4,9(11)-dien-3-one.

Diagram 1



7.



7

formula I.

In a first step of the process according to the invention, first the C-17 β -hydroxy group is protected by silylation with the formation of intermediate product 2. With hydride-transferring reagents, such as, e.g., with sodium borohydride or lithium

Although conceivable in principle, iodide 4 cannot be converted directly into end product 6 of general formula I by treatment with acid in a one-stage process. Having the process according to the invention proceed in steps is essential to the success of the process.

The synthesis that is shown in the example of iodine for radical X of general formula I is also performed analogously for the production of bromide or the radiolabeled halides.

By the use of almost stoichiometric amounts of halogens, in particular when using radiohalogens, the process according to the

invention is not only economical and environmentally safe, but it also makes possible the production of end compounds with high specific activity.

The substances of general formula I bind with high affinity to the androgen receptor despite a voluminous halogen substituent at the C-19 position.

Because of their biochemical and pharmacokinetic properties, the compounds according to the invention are extremely well suited for use in diagnostic processes.

Thus, e.g., iodide 6 (Formula I, X = I) with an IC_{50} value of 57 nmol/l shows a slight weakening of the binding affinity in comparison to the reference standard (3H -methyltrienolone R 1881), but it remains in an order of magnitude that shows a large degree of specific binding to the human androgen receptor in the prostate tissue.


The graphic visualization of the prostate requires, however, not only a large degree of specific binding, but it also requires little or almost no binding to transport proteins in the serum (S. J. Brandes and J. E. Katzenellenbogen, *Nucl. Med. Biol.* 15, 53-67, 1988). Decisive serum protein for the transport of androgens is SHBG (steroid hormone binding globulin). The SHBG affinity of iodide 6 compared to the standard DHT (5α -dihydrotestosterone) is reduced by a factor of 197. Thus, another requirement for the contrast-rich imaging of androgen-receptor-containing tissue is met.

The subject of the invention is therefore also the use of the compounds of general formula I as a diagnostic agent

according to claims 9 and 10. A preferred use is carried out for graphic visualization of the prostate and for early detection of pathophysiological changes thereof.

In addition to the use for diagnostic purposes, the non-labeled compounds of Formula I according to the invention are also valuable starting products for the production of new, unusual substituted steroids according to claim 11.

The silylation of the 17β -hydroxy group of the C-19-halogen-substituted steroids of the androst-9(11)-ene series according to the invention thus results in a 17β -silyl ether of general formula Ia




Ia

in which X = halogen, selected from Br, I, and which represents an important intermediate product for the further synthesis in a so-called tandem process to the new compounds of general formula II. Moreover, the intermediate products of Formula Ia are used for the production of the new $6\beta,19$ -cycloandrosta-4,9(11)-dienes of general formula III.


Shown in the example of 17β -(tert-butyltrimethylsilyloxy)-19-iodo-androsta-4,9(11)-dien-3-one 8, the reaction with mercaptoacetic acid methyl ester in the presence of a suitable base thus results in the formation of a thia-bridged derivative

9. Starting products can also be the other non-labeled 17 β -silylated C-19-halogen derivatives.




In this way, the functional group at C-19 is used to achieve a C-C linkage with the tertiary position C-5. Of course, the stereoselective introduction of functional groups in the tertiary positions of the steroid skeleton is a problem of preparative chemistry, for which general solutions are not available. Thus, specifically the introduction of a 5 β -methyl group by reaction of testosterone with organometallic reagents is known (e.g., C. Petrier et al., *Tetrahedron Lett.* 25, 3463, 1984), but is not suitable for the introduction of higher alkyl substituents or functionally substituted alkyl groups.

Thia-bridged derivative 9 is then reacted to form compounds of general formula II



with a radical R in the meaning of:




in which n can assume the values of 0-5, and radicals R¹ and R², independently of one another, stand for hydrogen or a straight-chain or branched, saturated or unsaturated hydrocarbon radical with up to 18 C atoms, whereby this radical optionally can contain additional functional groups and carbocyclic or heterocyclic ring elements.

According to the empirical findings from the normal series (9(11)-saturated) described in the literature, the result of the reaction of silylated halide Ia, e.g., iodide 8, with mercaptoacetic acid methyl ester was not predictable. As described by Halpern et al. (Steroids 4, 1-30, 1964), Santaniello and Caspi (J. Steroid Biochem. 7, 223-227, 1976) and Wright et al. (J. Chem. Soc. Perkin Trans. I, 1989, 1647-1655), the nucleophilic substitution at C-19 in the presence of the 3-oxo-4-ene structural element is extremely hampered and mainly results in skeletal restructuring.

All the more surprising is the smooth course of the reaction of a compound of Formula Ia → thia-bridged derivative 9, which can be interpreted mechanistically as a nucleophilic halogen-sulfur exchange with subsequent Michael addition (tandem process).

Diagram 2 illustrates a synthesis method by way of example:

Diagram 2



The process that is described by Diagram 2 offers a number of possibilities for producing derivatives of general formula II. It is obvious that, e.g., intermediate products 13 and 14 produce


an abundance of compounds for the production of such new steroids.

The compounds of general formula II are a new class of antiandrogenically active steroids and thus are suitable for the treatment of androgen-dependent diseases (prostate carcinoma, prostate hyperplasia).

The subjects of the invention are therefore also the compounds of general formula II according to claim 12, process for their production according to claim 13 and their use according to claim 14.


The new compounds of general formula III are produced according to claim 17 from the 17β -silyl ether of general formula Ia.

The treatment of silylated iodide 8 of general formula Ia with a non-nucleophilic base (e.g., sodium hydride, triethylamine, fluoride) in an aprotic solvent (e.g., THF, DMF) results in the formation of cyclosteroid 18.



After conventional silyl ether cleavage (tetrabutylammonium fluoride), the new testosterone derivative 19, the 17β -hydroxy- $6\beta,19$ -cycloandrosta-4,9(11)-dien-3-one, is produced. By standard

The subjects of the invention are consequently also the new 6 β ,19-cycloandrostadienes of formula III of claim 16, as well as processes for their production and their use according to claim 21.



111

X = O or the grouping 17 β -OR, 17 α -H, with R in the meaning of H, C1-C10-alkyl, C1-C10-acyl, whereby the acyl radical is derived from an aliphatic or aromatic carboxylic acid.

In addition, the subjects of the invention are the 17 β -silyl ether of general formula Ia, which are produced as intermediate products from the compounds of general formula I according to the invention and common starting products for the new 5 β -substituted steroids of general formula II and the 6 β ,19-cycloandrostadienes of Formula III.

The invention also includes pharmaceutical agents according to claim 24, which as active components contain at least one compound of general formula I, II and/or III.

The examples below are to explain the invention in more detail, without limiting the latter thereto.

a. 17 β -(tert-Butyldimethylsilyloxy)-3,3-(2,2-dimethyl-trimethylenedioxy)-10 β -formyl-androst-9(11)-en-5 α -ol (2)

b. 17β-(tert-Butyldimethylsilyloxy)-3,3-(2,2-dimethyltrimethylenedioxy)-androst-9(11)-ene-5α,19-diol (3)

A solution of 2.58 g (4.97 mmol) of the product, obtained under a., in 26 ml of THF and 26 ml of methanol is mixed at 0°C with 211 mg (5.57 mmol) of sodium borohydride, and it is stirred for 1.5 hours at 0°C. After the addition of 105 mg (2.78 mmol) of NaBH₄ was again performed, it is stirred for another 75 minutes at 0°C, the reaction mixture was then stirred into ice water and extracted with ethyl acetate. The crystalline crude product (2.46 g, 95% of theory) is used without further

purification in the next step. ^1H -NMR (CDCl_3 , 300 MHz): δ = 0.67 ppm (s, 3H, H-18); 0.87 (s, 9H, Si-tBu); 0.93 and 0.99 (2s; 3H, ketal-Me each); 3.41-3.73 (m, 7H, CH_2OH , CH_2O , H-17); 4.51 (s, 1H, 5α -OH); 5.45 (d, J = 7.5 Hz, 1H, H -11).

c. 17 β -(tert-Butyldimethylsilyloxy)-3,3-(2,2-dimethyl-trimethylenedioxy)-19-iodo-androst-9(11)-en-5 α -ol (4)

20.72 g (79.0 mmol) of triphenylphosphine and 5.38 g (79.0 mmol) of imidazole are added at room temperature to a solution of 16.07 g (30.9 mmol) of the alcohol, produced according to Example 1b, in 225 ml of THF. While being cooled with ice water, 10.03 g (39.5 mmol) of iodine is then added in portions over about 5 minutes to the reaction mixture and then stirred for 1.5 hours at ambient temperature (23°C). For working-up, the reaction solution is poured into about 2 l of a 5% aqueous sodium thiosulfate solution, which was cooled to +5°C and extracted with ethyl acetate. After chromatography of the crude product on silica gel with hexane/ethyl acetate 9:1, 17.0 g (87.2% of theory) of the iodide is obtained as a colorless oil. ^1H -NMR (CDCl_3 , 300 MHz): δ = 0.80 ppm (s, 3H, H-18); 0.88 (s, 9H, Si-tBu); 0.92 and 2.00 (2s; 3H, ketal-Me each); 3.41-3.74 (m, 7H, CH_2I , CH_2O , H-17); 4.50 (s, 1H, 5α -OH); 5.30 (d, J = 7.5 Hz, 1H, H-11).

- d) 17 β -(tert-Butyldimethylsilyloxy)-3,3-(2,2-dimethyltrimethylenedioxy)-19-iodo-androsta-5,9(11)-diene (5a) and 17 β -(tert-butyldimethylsilyloxy)-3,3-(2,2-dimethyltrimethylenedioxy)-19-iodo-androsta-4,9(11)-diene (5b)

The product that is obtained under Example 1c (16.95 g, 26.9 mmol) is dissolved in 85 ml of pyridine. While being cooled with ice water, 3.91 ml (53.8 mmol) of thionyl chloride is added in drops over about 15 minutes and stirred for 45 more minutes while being cooled with ice water. The thus produced yellow suspension is stirred into about 1 l of a mixture that consists of saturated common salt solution (500 ml) and saturated NaHCO₃ solution and extracted with ethyl acetate. The crude product that is obtained after the EE extracts are dried on Na₂SO₄ and concentrated by evaporation is taken up several times in toluene for the removal of pyridine radicals and concentrated by evaporation in a vacuum. In this way, 14.85 g of a crude mixture of the isomeric dehydration products, which is used without further purification in the subsequent reaction, is obtained.

- e. 17 β -Hydroxy-19-iodo-androsta-4,9(11)-dien-3-one (6)

A solution of 14.85 g (24.3 mmol) of the isomer mixture in 325 ml of dichloromethane and 32 ml of water that is obtained under 1d is stirred for 4 hours at room temperature after 64.6 ml (870 mmol) of trifluoroacetic acid is added. Then, it is diluted with 200 ml of dichloromethane, washed with saturated common salt solution and NaHCO₃ solution, dried on sodium sulfate and concentrated by evaporation. The crude product is

Example 2: 19-Bromo-17 β -hydroxy-androsta-4,9(11)-dien-3-one

Example 3: 17 β -(tert-Butyldimethylsilyloxy)-3-oxo-2'H,5'H-thieno[3',4':5,10]-5 β -estr-9(11)-ene-2' ξ -carboxylic acid methyl ester

A reaction solution that consists of 7.36 g (17.9 mmol) of 17 β -hydroxy-19-iodo-androsta-4,9(11)-dien-3-one, 7.48 g (110 mmol) of imidazole and 9.72 ml (32.1 mmol) of tert-

butyldimethylchlorosilane (3.3 M in hexane) in 40 ml of DMF is stirred for 16 hours at room temperature and worked up as usual (Example 1a). 8.95 g (95% of theory) of the silyl ether is obtained. $^1\text{H-NMR}$ (CDCl_3 , 300 MHz): δ = 0.82 ppm (s, 3H, H-18); 0.90 (s, 9H, Si-tBu); 3.57 (t, J = 11 Hz, 2H, H-19); 3.68 (t, J = 9 Hz, 1H, H-17); 5.59 (d, J = 7.5 Hz, 1H, H-11); 5.85 (d, J = 1.5 Hz, 1H, H-4).

b. 17 β -(tert-Butyldimethylsilyloxy)-3-oxo-2'H,5'H-thieno[3',4':5,10]-5 β -estr-9(11)-ene-2' ξ -carboxylic acid methyl ester

2.92 ml (32.2 mmol) of mercaptoacetic acid methyl ester is added in drops to a suspension of 1.38 g (46.1 mmol) of sodium hydride (80% in oil) in 92.5 ml of dimethylformamide while being cooled with ice water within 3 minutes, and it is stirred for another 15 minutes. Then, a solution of 8.95 g (17.7 mmol) of 17 β -(tert-butyldimethylsilyloxy)-19-iodo-androsta-4,9(11)-dien-3-one in 111 ml of DMF is added drop by drop and stirred for 3 hours at room temperature. For working-up, it is poured into ice-cold saturated $\text{NH}_4\text{-Cl}$ solution and extracted with ethyl acetate. After chromatography of the crude product on silica gel with hexane/ethyl acetate 3:1, 7.08 g (79.2% of theory) of the title compound is obtained as an isomer mixture on C-2'. $^1\text{H-NMR}$ (CDCl_3 , 300 MHz, 2'(R)-isomer): δ = 0.62 ppm (s, 3H, H-18); 0.89 (s, 9H, Si-tBu); 3.42 and 3.68 (2d, J = 10 Hz; 1H, H-19 each); 3.70 (t, J = 9 Hz, 1H, H-17); 3.75 (s, 3H, COOMe); 4.01 (s, 1H, H-2'); 5.83 (d, J = 7.5 Hz, 1H, H-11).

From 2.35 g (4.64 mmol) of the reduction product that is obtained under 4a, 2.41 g (35.4 mmol) of imidazole and 3.14 ml (10.4 mmol) of a 3.3 M hexane solution of tert-butyldimethylchlorosilane in 10.2 ml of DMF, 2.67 g (92.6% of theory) of the silyl ether is obtained under the conditions of Example 2a.

For analytical purposes, a sample of the crude product that consists of ethanol is recrystallized. In this way, the 2' (R)-isomer can be obtained in a pure state. Melting point 177°C, $[\alpha]_D +16.3^\circ$ (CHCl_3 , $C = 0.516$). $^1\text{H-NMR}$ (CDCl_3 , 300 MHz): $\delta = 0.62$ ppm (s, 3H, H-18); 0.88 and 0.90 (2s; 9H, Si-tBu each); 2.25 and 3.22 (2d, $J = 10$ Hz; 1H, H-19 each); 3.65 (t, $J = 9$ Hz, 1H, H-17); 3.70 and 3.87 (2m; 1H, CH_2OH each); 4.06 (s(br), 1H, H-3); 4.95 (q, $J = 6$ and 2 Hz, 1H, H-2'); 5.59 (d, $J = 7.5$ Hz, 1H, H-11).

- d. 3 β ,17 β -Bis-(tert-butyldimethylsilyloxy)-5-(2-hydroxyethyl)-5 β -androst-9(11)-ene (13)

A suspension of 2.36 g (3.98 mmol) of the product that is obtained above and 10 g of Raney nickel in 92 ml of ethanol is refluxed for 3 hours. After cooling, the reaction solution is mixed with 100 ml of dichloromethane and filtered on Celite. The filter residue is washed thoroughly with dichloromethane. After the filtrate is concentrated by evaporation, a crude product of 2.36 g, which is chromatographed on silica gel with hexane/ethyl acetate, remains. The main fraction yields 1.88 g (83.9% of theory) of the crystalline desulfurization product.

- e. 3 β ,17 β -Bis-(tert-butyldimethylsilyloxy)-5-(2-iodoethyl)-5 β -androst-9(11)-ene (14)

Under the conditions of Example 1c, 1.85 g (82.3% of theory) of the iodide is obtained from 1.88 g (3.34 mmol) of the alcohol that is formed under 4d, 2.24 g (8.53 mmol), 580 mg (8.53 mmol) of imidazole and 1.09 g (4.29 mmol) of iodine in 24.3 ml of THF after analogous implementation and working-up. $^1\text{H-NMR}$ (CDCl_3 , 300 MHz): δ = 0.64 ppm (s, 3H, H-18); 0.88 and 0.93 (2s; 9H, Si-tBu each); 0.99 (s, 3H, H-19); 3.20 and 3.42 (2m; 1H, CH_2I each); 3.63 (t, J = 9 Hz, 1H, H-17); 4.05 (s(br), 1H, H-3); 5.42 (d, J = 7.5 Hz, 1H, H-11).

- f. 3 β ,17 β -Bis-(tert-butyldimethylsilyloxy)-5-[2-(2-pyrimidylsulfanyl)-ethyl]-5 β -androst-9(11)-ene (15)

A suspension of 111 mg (2.54 mmol) of NaH (55% in oil) in 5 ml of DMF is stirred after the addition of 199 mg (1.77 mmol) of pyrimidine-2-thiol for 15 minutes at room temperature and then mixed drop by drop with a solution of 655 mg (0.97 mmol) of the iodide that is obtained above in 6 ml of THF and 6 ml of diethyl ether. It is stirred for 21 hours at ambient temperature, poured into ice-cold, saturated NaCl solution and extracted with ethyl acetate. After chromatography on silica gel with hexane/ethyl acetate 9:1, 600 mg (93.8% of theory) of the crystalline substitution product is obtained.

- g. 5-[2-(2-Pyrimidylsulfanyl)-ethyl]-5 β -androst-9(11)-ene-3 β ,17 β -diol (16)

A solution of 590 mg (0.89 mmol) of the product, obtained under Example 4f, in 26.1 ml of THF is stirred for 8 hours at 60°C after the addition of 2.76 g (8.74 mmol) of tetrabutylammonium fluoride (Bu₄NF · 3 H₂O). After cooling, it is poured into saturated NaHCO₃ solution and extracted with ethyl acetate. After chromatography on silica gel with hexane/ethyl acetate 4:1 and recrystallization of the main product that consists of ethanol/diisopropyl ether, 250 mg (67.5% of theory) of the title compound with a melting point of 209°C, [α]_D -27.4° (MeOH, C = 0.507) is obtained. ¹H-NMR (DMSO-d₆, 300 MHz): δ = 0.59 ppm (s, 3H, H-18); 0.93 (s, 3H, H-19); 3.56 (m, 1H, H-17); 3.93 (s(br), 1H, OH); 4.30 (s(br), 1H, H-3); 4.40 (m, 1H, OH);

5.46 (d, $J = 7.5$ Hz, 1H, H-11); 7.17 (t, $J = 5$ Hz, 1H, H-5');
8.60 (d, $J = 5$ Hz, 2H, H-4' and H-6').

When using the corresponding thiols, additional end products are obtained according to the process of Example 4:

1. 5-[2-(Heptylsulfanyl)-ethyl]-5 β -androst-9(11)-ene-3 β ,17 β -diol, melting point 126°C (hexane/ethyl acetate), $[\alpha]_D +15.0^\circ$ (CHCl₃, $c = 0.453$).
2. 5-[2-[(1-Methyl-1H-imidazole-2-yl)sulfanyl]ethyl]-5 β -androst-9(11)-ene-3 β ,17 β -diol, melting point 212° (hexane/ethyl acetate), $[\alpha]_D +85.5^\circ$ (CHCl₃, $c = 0.503$).
¹H-NMR (CDCl₃, 300 MHz): $\delta = 0.69$ ppm (s, 3H, H-18); 1.01 (s, 3H, H-19); 3.55 (s, 3H, Nme); 3.74 (t, $J = 8$ Hz, 1H, H-17); 5.48 (m, 1H, H-11); 6.87 (d, $J = 0.5$ Hz, 1H, imidazole-H); 7.00 (d, $J = 0.5$ Hz, 1H, imidazole-H).
3. 5-[2-(Benzothiazole-2-yl)-sulfanyl]-5 β -androst-9(11)-ene-3 β ,17 β -diol, $[\alpha]_D +99.0^\circ$ (CHCl₃, $c = 0.5$). ¹H-NMR (CDCl₃, 300 MHz): $\delta = 0.69$ ppm (s, 3H, H-18); 1.01 (s, 3H, H-19); 4.18 (s, 1H, H-3); 5.50 (m, 1H, H-11); 7.27 (dd, $J = 7.5$ and 8 Hz, 1H, arom.-H); 7.41 (dd, $J = 7.5$ and 8 Hz, 1H, arom.-H); 7.73 (d, $J = 7.5$ Hz, 1H, arom.-H); 7.88 (d, $J = 7.5$ Hz, 1H, arom.-H).
4. 5-[2-(Thiene-2-yl)-sulfanyl]ethyl-5 β -androst-9(11)-ene-3 β ,17 β -diol, melting point 156°C $[\alpha]_D +3.0^\circ$ (CHCl₃, $c = 0.47$). ¹H-NMR (CDCl₃, 300 MHz): $\delta = 0.65$ ppm (s, 3H, H-18); 0.99 (s, 3H, H-19); 2.75 (m, 1H, CH₂S); 3.08 (m, 1H, CH₂S); 3.72 (t, $J = 8$ Hz, 1H, H-17); 4.06 (s(br),

1H, H-3); 5.45 (m, 1H, H-11); 6.95 (dd, J = 4 and 7 Hz, 1H, thienyl-H); 7.12 (dd, J = 1 and 4 Hz, 1H, thienyl-H); 7.32 (dd, J = 1 and 7 Hz, 1H, thienyl-H).

Example 5: 5-Ethyl-5 β -androst-9(11)-ene-3 β ,17 β -diol

A solution of 2.25 g (3.34 mmol) of 3 β ,17 β -bis-(tert-butyldimethylsilyloxy)-5-(2-iodoethyl)-5 β -androst-9(11)-ene (Example 4e) is heated to 80°C after the addition of 50 mg of azobisisobutyronitrile and mixed drop by drop with 2 ml of tributyltin hydride. It is stirred for another 60 minutes at 80°C and poured after cooling into 150 ml of a 5% aqueous sodium fluoride solution. The crude product that is obtained after extraction with ethyl acetate is treated with tetrabutylammonium fluoride in THF under the conditions of Example 1g. After chromatography, 720 mg (67.8%) of the title compound with a melting point of 165°C (hexane/ethyl acetate) is obtained. $[\alpha]_D^{25} +18.8^\circ$ (CHCl₃, c = 0.493).

Example 6: 3 β ,17 β -Dihydroxy-5 β -androst-9(11)-ene-5-propanenitrile

a. 3 β ,17 β -Bis-(tert-butyldimethylsilyloxy)-5 β -androst-9(11)-ene-5-propanenitrile

A suspension of 2.23 g (3.31 mmol) of 3 β ,17 β -bis-(tert-butyldimethylsilyloxy)-5-(2-iodoethyl)-5 β -androst-9(11)-ene (Example 4e) and 948 mg (15.11 mmol) of KCN in 48 ml of DMF is stirred for 36 hours at 60°C under argon. After cooling, it is poured into ice-cold 1N NaOH solution and extracted with

dichloromethane. After chromatography of the crude product on silica gel with hexane/ethyl acetate, 1.56 g (75.5% of theory) of the nitrile with a melting point of 194-195°C (hexane), $[\alpha]_D^{25} +15.0^\circ$ (CHCl_3 , $c = 0.5$), is obtained.

a. 3 β ,17 β -Dihydroxy-5 β -androst-9(11)-ene-5-propanenitrile

A solution of 300 mg (0.52 mmol) of the nitrile above in 30 ml of THF is stirred for 2 hours at 60°C after the addition of 2.67 g (10.3 mmol) of tetrabutylammonium fluoride and worked up under the conditions of Example 1g. After crystallization from hexane/ethyl acetate, 140 mg (77.8%) with a melting point of 203°C, $[\alpha]_D^{25} +20.9^\circ$ (CHCl_3 , $c = 0.496$), is obtained. $^1\text{H-NMR}$ (CDCl_3 , 300 MHz): $\delta = 0.69$ ppm (s, 3H, H-18); 1.01 (s, 3H, J-19); 2.52-2.75 (m, 2H, CH_2CN); 3.73 (t, $J = 8$ Hz, 1H, H-17); 4.10 (s(br), 1H, H-3); 5.48 (m, 1H, H-11).

Example 7: 17 β -Hydroxy-6 β ,19-cycloandrosta-4,9(11)-dien-3-one

a. 17 β -(tert-Butyldimethylsilyloxy)-6 β ,19-cycloandrosta-4,9(11)-dien-3-one (18)

A suspension of 650 mg (14.9 mmol) of NaH (55% in oil) in 30 ml of DMF is mixed at room temperature drop by drop with a solution of 3.00 g (5.70 mmol) of 17 β -(tert-butyldimethylsilyloxy)-19-iodo-androsta-4,9(11)-dien-3-one (8) in 35 ml of DMF and 6.5 ml of diethyl ether. It is stirred for 2.5 hours at 25°C, then poured into ice-cold, saturated NaCl solution and extracted with ethyl acetate. After chromatographic purification, 1.98 g

(79.2% of theory) of crystalline 17 β -(tert-butyldimethylsilyloxy)-6 β ,19-cycloandrosta-4,9(11)-dien-3-one is obtained.

b. 17 β -Hydroxy-6 β ,19-cycloandrosta-4,9(11)-dien-3-one (19)


A solution of 680 mg (1.33 mmol) of the product that is obtained above and 4.09 g (13.0 mmol) of tetrabutylammonium fluoride ($\text{Bu}_4\text{NF} \cdot 3 \text{H}_2\text{O}$) is stirred for 2 hours at 60°C. After working-up analogously to Example 3g and chromatography of the crude product on silica gel with ethyl acetate, 370 mg (97.8% of theory) of the title compound is obtained. Recrystallization of a sample that consists of hexane/ethyl acetate yields colorless crystals with a melting point of 176-179°C, $[\alpha]_D -232.9^\circ$ (CHCl_3 , $c = 0.502$). $^1\text{H-NMR}$ (CDCl_3 , 300 MHz): $\delta = 0.80$ ppm (s, 3H, H-18); 3.78 (t, $J = 9$ Hz, 1H, H-17); 5.60 (m, 2H, H-4 and H-11).

Example 8: 6 β ,19-Cycloandrosta-4,9(11)-diene-3,17-dione

A solution of 450 mg (1.58 mmol) of the alcohol that is obtained under Example 7b is mixed drop by drop with 0.98 ml of Jones reagent while being cooled with ice water, and it is stirred for 60 more minutes at room temperature. Then, it is poured into 5% aqueous sodium thiosulfate solution and extracted with ethyl acetate. After chromatography on silica gel and crystallization from hexane/ethyl acetate, 138 mg (30.9%) of the ketone with a melting point of 139°C, $[\alpha]_D -109.2^\circ$ (CHCl_3 , $c = 0.511$), is obtained. $^1\text{H-NMR}$ (CDCl_3 , 300 MHz): $\delta = 0.95$ ppm (s, 3H, H-18); 3.33 (t, $J = 6$ Hz, 1H, H-6); 5.64 (m, 2H, H-4, H-11).

Claims:

1. 17 β -Hydroxy-19-halogen-androsta-4,9(11)-dien-3-ones of general formula I,



in which X = a halogen radical or a radiohalogen radical.

2. 17 β -Hydroxy-19-halogen-androsta-4,9(11)-dien-3-ones according to claim 1, characterized in that X = Br, I, ¹²⁵I, ¹³¹I, ⁸²Br or ⁷⁷Br.

3. 17 β -Hydroxy-19-halogen-androsta-4,9(11)-dien-3-ones according to one of claims 1 or 2, characterized by

17 β -Hydroxy-19-iodo-androsta-4,9(11)-dien-3-one,

17 β -Hydroxy-19-¹²⁵iodo-androsta-4,9(11)-dien-3-one or

19-Bromo-17 β -hydroxy-androsta-4,9(11)-dien-3-one.

4. Process for the production of 17 β -hydroxy-19-halogen-androsta-4,9(11)-dien-3-ones of general formula I according to one of claims 1 to 3, wherein starting from 3,3-(2,2-dimethyl-trimethylenedioxy)-10 β -formyl-androst-9(11)-ene-5 α ,17 β -diol

a) The C-17 β -hydroxy group is protected by silylation,

b) The 10 β -formyl group is reduced to the C-19-hydroxy compound,

- c) The thus produced 17 β -silylated-3,3-(2,2-dimethyl-trimethylenedioxy)-androst-9(11)-ene-5 α ,19-diol is reacted with elementary halogen or radiohalogen, selected from Br or I, to form 17 β -silylated-3,3-(2,2-dimethyl-trimethylenedioxy)-19-halogen-androst-9(11)-en-5 α -ol,
- d) Water is cleaved off, and
- e) The thus produced isomer mixture that consists of 17 β -silylated-3,3-(2,2-dimethyl-trimethylenedioxy)-19-halogen-androsta-5,9(11)-diene and 17 β -silylated-3,3-(2,2-dimethyl-trimethylenedioxy)-19-halogen-androsta-4,9(11)-diene is mixed with a strong protonic acid for the formation of target compounds I.

5. Process according to claim 4, wherein the reduction to the C-19-hydroxy compound is carried out with sodium borohydride, lithium aluminum hydride or diisobutyl aluminum hydride.

6. Process according to claim 4 or 5, wherein the halogen or radiohalogen is added in a small excess.


7. Process according to one of claims 4 to 6, wherein the dehydration is carried out under standard conditions, preferably with thionyl chloride/pyridine.

8. Process according to one of claims 4 to 7, wherein trifluoroacetic acid, sulfuric acid or methanesulfonic acid is used as a strong protonic acid.

9. Use of the compounds of general formula I according to one of claims 1 to 3 as a diagnostic agent.


10. Use according to claim 9 for graphic visualization of the prostate and for early detection of pathophysiological changes.

11. Use of the non-labeled compounds of general formula I according to one of claims 1 to 3 as starting products for the production of 5 β -substituted androst-9(11)-enes of general formula II with radical R in the meaning of: $R = -(\text{CH}_2)_n-\text{CH}_2-\text{R}^1$, $-(\text{CH}_2)_n-\text{CH}_2-\text{OR}^1$, $-(\text{CH}_2)_n-\text{CH}_2-\text{OCOR}^1$, $-(\text{CH}_2)_n-\text{CH}_2-\text{SR}^1$, $-(\text{CH}_2)_n-\text{CH}_2-\text{NR}^1\text{R}^2$, $-(\text{CH}_2)_n-\text{CHO}$, $-(\text{CH}_2)_n-\text{CN}$, in which n can assume the values of 0-5, and radicals R^1 and R^2 , independently of one another, stand for hydrogen or a straight-chain or branched, saturated or unsaturated hydrocarbon radical with up to 18 C atoms, whereby this radical optionally can contain additional functional groups and carbocyclic or heterocyclic ring elements.



12. Compounds of general formula II with radical R in the meaning of: $R = -(\text{CH}_2)_n-\text{CH}_2-\text{R}^1$, $-(\text{CH}_2)_n-\text{CH}_2-\text{OR}^1$, $-(\text{CH}_2)_n-\text{CH}_2-\text{OCOR}^1$, $-(\text{CH}_2)_n-\text{CH}_2-\text{SR}^1$, $-(\text{CH}_2)_n-\text{CH}_2-\text{NR}^1\text{R}^2$, $-(\text{CH}_2)_n-\text{CHO}$, $-(\text{CH}_2)_n-\text{CN}$, in which n can assume the values of 0-5, and radicals R^1 and R^2 , independently of one another, stand for hydrogen or a straight-chain or branched, saturated or unsaturated hydrocarbon radical


with up to 18 C atoms, whereby this radical optionally can contain additional functional groups and carbocyclic or heterocyclic ring elements.



13. Process for the production of 5 β -substituted androst-9(11)-enes of general formula II according to claim 12 by reaction of a compound of general formula I to form 17 β -silyl ether Ia and further reaction with mercaptoacetic acid methyl ester for the formation of 17 β -silylated-3-oxo-2'H,5'H-thieno[3',4':5,10]-5 β -estr-9(11)-ene-2' ξ -carboxylic acid methyl ester, which then is reacted according to processes that are known in the art analogously to Diagram 2 to form the target compounds of Formula II.


14. Use of the compounds of general formula II according to claim 12 for treatment of androgen-dependent diseases.

15. Use of the non-labeled compounds of general formula I according to one of claims 1 to 3 as starting products for the production of 6 β ,19-cycloandrosta-1,4-dienes of general formula III, in which X = O or the grouping 17 β -OR, 17 α -H, with R in the meaning of H, C1-C10-alkyl, C1-C10-acyl, whereby the acyl radical is derived from an aliphatic or aromatic carboxylic acid.



III

16. 6 β ,19-Cycloandrostadienes of Formula III



III

in which

X = O or the grouping 17 β -OR, 17 α -H, with R in the meaning of H, C1-C10-alkyl, C1-C10-acyl, whereby the acyl radical is derived from an aliphatic or aromatic carboxylic acid.

17. Process for the production of the 6 β ,19-cycloandrostadienes of Formula III according to claim 16, wherein a compound of general formula I is reacted to form 17 β -silyl ether Ia and the latter is treated with a non-nucleophilic base in a solvent, and then the silyl ether is further cleaved off while a cyclosteroid of general formula III is obtained, and the latter then is optionally converted by standard processes, such as esterification, etherification, oxidation, into further compounds of general formula III.


18. Process according to claim 17, wherein it is treated with sodium hydride, triethylamine, fluoride as a non-nucleophilic base.

19. Process according to claim 17 or 18, wherein the base treatment is carried out in an aprotic solvent.

20. Process according to claim 19, wherein the aprotic solvent is THF or DMF.

21. Use of the 6 β ,19-cycloandrostadienes of general formula III according to claim 16 as an aromatase inhibitor and 5 α -reductase inhibitor.

22. 17 β -Silyl ether of general formula Ia



in which X = halogen, selected from Br or I.

23. 17 β -Silyl ether according to claim 22, characterized by the 17 β -(tert-butyltrimethylsilyloxy)-19-halogen-androsta-4,9(11)-dien-3-ones, preferably

17 β -(tert-butyltrimethylsilyloxy)-19-iodo-androsta-4,9(11)-dien-3-one,

17 β -(tert-butyltrimethylsilyloxy)-19-bromo-androsta-4,9(11)-dien-3-one.

(12) NACH DEM VERTRAG ÜBER DIE INTERNATIONALE ZUSAMMENARBEIT AUF DEM GEBIET DES
PATENTWESENS (PCT) VERÖFFENTLICHTE INTERNATIONALE ANMELDUNG

(19) Weltorganisation für geistiges Eigentum
Internationales Büro



(43) Internationales Veröffentlichungsdatum
25. Januar 2001 (25.01.2001)

PCT

(10) Internationale Veröffentlichungsnummer
WO 01/05805 A3

(51) Internationale Patentklassifikation⁷: C07J 1/00, A61K 31/565, G01N 33/60, C07J 51/00, 53/00, 21/00, 71/00, 43/00, A61P 5/36, 5/32

(21) Internationales Aktenzeichen: PCT/DE00/02390

(22) Internationales Anmeldedatum:
17. Juli 2000 (17.07.2000)

(25) Einreichungssprache: Deutsch

(26) Veröffentlichungssprache: Deutsch

(30) Angaben zur Priorität:
199 34 088.9 15. Juli 1999 (15.07.1999) DE

(71) Anmelder (für alle Bestimmungsstaaten mit Ausnahme von US): SCHERING AKTIENGESELLSCHAFT [DE/DE]; Müllerstrasse 178, D-13353 Berlin (DE).

(72) Erfinder; und

(75) Erfinder/Anmelder (nur für US): NEEF, Günter [DE/DE]; Markgraf-Albrecht-Strasse 4, D-10711 Berlin (DE). GOLDE, Roland [DE/DE]; Schonfliesser Strasse 24, D-16562 Bergfelde (DE). FRITZEMEIER, Karl-Heinrich [DE/DE]; Rabenstrasse 5a, D-13505 Berlin (DE).

(81) Bestimmungsstaaten (national): AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Bestimmungsstaaten (regional): ARIPO-Patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), eurasisches Patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), europäisches Patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI-Patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Veröffentlicht:


— mit internationalem Recherchenbericht

(88) Veröffentlichungsdatum des internationalen
Recherchenberichts: 13. September 2001

Zur Erklärung der Zweibuchstaben-Codes, und der anderen Abkürzungen wird auf die Erklärungen ("Guidance Notes on Codes and Abbreviations") am Anfang jeder regulären Ausgabe der PCT-Gazette verwiesen.

(54) Title: NOVEL C-19-HALOGEN-SUBSTITUTED, 5-SUBSTITUTED, 5-SUBSTITUTED OR 6,10 CARBOCYCLICALLY CONDENSED STEROIDS OF THE ANDROST-9(11)-ENE-SERIES, METHODS FOR THE PRODUCTION AND USE THEREOF

(54) Bezeichnung: NEUE C-19-HALOGENSUBSTITUIERTE, 5-SUBSTITUIERTE, 5-SUBSTITUIERTE ODER 6,10-CARBOZYKLISCH-KONDENSIERTE STEROIDE DER ANDROST-9(11)-EN-REIHE, VERFAHREN ZU IHRER HERSTELLUNG SOWIE IHRE VERWENDUNG



(57) Abstract: The invention relates to novel C-19-halogen-substituted steroids of the androst-9(11)-ene series, i.e. 17 β -hydroxy-19-halogen-androsta-4,9(11)-diene-3-one of general formula (I) and to methods for the production thereof. The invention also relates to the use of novel radiohalogen-marked compounds of formula I as radiopharmaceuticals. The invention further relates to non-marked compounds(I) of formula I as initial products for the production of novel biologically effective 5 β -substituted Androst-9(11)-enes of general formula (II) and novel 6 β 19-cycloandrostadienes of formula (III), in addition to methods and uses thereof.

(57) Zusammenfassung: Die Erfindung betrifft neue C-19-halogensubstituierte Steroide der Androst-9(11)-en-Reihe, nämlich 17 β -Hydroxy-19-halogen-androsta-4,9(11)-dien-3-one der allgemeinen Formel (I), und Verfahren zu ihrer Herstellung. Des weiteren ist die Verwendung der neuen radiohalogen-markierten Verbindungen der Formel (I), als Radiopharmaka Gegenstand der Erfindung sowie die Verwendung der nichtmarkierten Verbindungen der Formel (I) als Ausgangsprodukte zur Herstellung von neuen biologisch wirksamen 5 β -substituierten Androst-9(11)-enen der allgemeinen Formel (II) und der neuen 6 β , 19-Cycloandrostadiene der Formel (III) sowie Verfahren zu deren Herstellung und ihre Verwendung.

WO 01/05805 A3

DECLARATION FOR PATENT APPLICATION

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name,

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

NOVEL C-19-HALOGEN-SUBSTITUTED STEROIDS OF THE ANDROST-9(11)-ENE-SERIES, METHODS FOR THE PRODUCTION AND USE THEREOF

the specification of which

☐ is attached hereto

☒ was filed on 17 JULY 2000 as United States Application Number or PCT International Application Number PCT/DE00/023690 and (if applicable) was amended on _____

I hereby authorize our attorneys to insert the serial number assigned to this application.

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is material to patentability as defined in 37 CFR §1.56.

I hereby claim foreign priority benefits under 35 U.S.C. §119(a)-(d) or §365(b) of any foreign application(s) for patent or inventor's certificate, or §365(a) of any PCT International application which designated at least one country other than the United States, listed below and have also identified below, by checking the box, any foreign application for patent or inventor's certificate, or PCT International application having a filing date before that of the application on which priority is claimed.

PRIOR FOREIGN/PCT APPLICATION(S) AND ANY PRIORITY CLAIMS UNDER 35 USC §119			
APPLICATION NO.	COUNTRY	DAY/MONTH/YEAR FILED	PRIORITY CLAIMED
199 34 088.9	GERMANY	15 JULY 1999	YES

I hereby claim the benefit under 35 U.S.C. §119(e) of any United States provisional application(s) listed below.

PROVISIONAL APPLICATION(S) UNDER 35 U.S.C. §119(e)	
APPLICATION NUMBER	FILING DATE

I hereby claim the benefit under 35 U.S.C. §120 of any United States application, or §365(c) of any PCT International application designating the United States, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT International application in the manner provided by the first paragraph of 35 U.S.C. §112.

I acknowledge the duty to disclose information which is material to patentability as defined in 37 CFR §1.56 which became available between the filing date of the prior application and the national or PCT International filing date of this application.

PRIOR U.S./PCT INTERNATIONAL APPLICATION(S) DESIGNATED FOR BENEFIT UNDER 37 U.S.C. §120		
APPLICATION NO.	FILING DATE	STATUS — PATENTED, PENDING, ABANDONED

I hereby appoint the following attorney(s) and/or agent(s) to prosecute this application and to transact all business in the Patent and Trademark Office connected herewith: I. William Millen (19,544); John L. White (17,746); Anthony J. Zelano (27,969); Alan E.J. Branigan (20,565); John R. Moses (24,983); Harry B. Shubin (32,004); Brion P. Heaney (32,542); Richard J. Traverso (30,595); John A. Sopp (33,103); Richard M. Lebovitz (37,067); John H. Thomas (33,460); Catherine M. Joyce (40,668); Nancy J. Axelrod (44,014); James T. Moore (35,619); James E. Ruland (37,432); Jennifer J. Branigan (40,921) and Robert E. McCarthy (46,044)

Send Correspondence to Customer Number 23599



23599

PATENT TRADEMARK OFFICE

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Full Name of sole or first inventor (given name, family name)	
<u>Gunter NEEF</u>	
Signature <i>Gunter Neef</i>	Date <u>27.05.02</u>
Residence <u>Berlin, Germany</u> <u>DEX</u>	Citizenship <u>Germany</u>
Post Office Address <u>Markgraf-Albrecht-Strasse 4, D-10711 Berlin Germany</u>	
Full Name of additional joint inventor (given name, family name)	
<u>Roland GOLDE</u>	
Signature <i>Roland Golde</i>	Date <u>21.05.02</u>
Residence <u>Bergfelde, Germany</u> <u>DEX</u>	Citizenship <u>Germany</u>
Post Office Address <u>Schonfliesser Strasse 24, D-16562 Berlin Germany</u>	
Full Name of additional joint inventor (given name, family name)	
<u>Karl-Heinrich FRITZEMEIER</u>	
Signature <i>Karl-Heinrich Fritzemeier</i>	Date <u>13.05.02</u>
Residence <u>Berlin, Germany</u> <u>DEX</u>	Citizenship <u>Germany</u>
Post Office Address <u>Rabenstrasse 5a, D-13505 Berlin Germany</u>	
Full Name of additional joint inventor (given name, family name)	
Signature	Date
Residence	Citizenship
Post Office Address	
Full Name of additional joint inventor (given name, family name)	
Signature	Date
Residence	Citizenship
Post Office Address	

☐ Additional joint inventors are named on separately numbered sheets attached hereto.